Oryzon Genomics, S.A.

ORY · BME · Spain

Public Market Listing

ORYBME

BME primary exchange listing

Live quotes, historical charts, and market capitalization for Oryzon Genomics, S.A. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
LSD1 / KDM1ASmall molecule
Acute Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$0——$1.7Mreport ↗

Oryzon Genomics reported revenue of $0M for H1 2025, with a net loss of €1.59 million, up 52.8% YoY, and a quarterly net burn of $1.74M. R&D spend and cash position were not disclosed.

The company said it expects to generate profits in Q3 2025 and noted that the H1 result does not include a recent €13.2 million CDTI aid package. It also reported receiving €52 million in financing between late 2024 and July 2025, including €30 million from a capital increase, while continuing various drug research programs.

View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1$0$2.5M—$1.8Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$14M$33M—report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-9M$0——$1.5Mreport ↗
2024-FY$0$9.0M$5.8M$4.0Mreport ↗